Detalles de la búsqueda
1.
Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
Ann Oncol
; 28(3): 642-650, 2017 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27993791
2.
Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities.
Cancer Metastasis Rev
; 34(4): 547-61, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25543191
3.
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Ann Oncol
; 26(7): 1346-52, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25878190
4.
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
Ann Oncol
; 26(5): 1012-1018, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25669829
5.
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response.
BMC Cancer
; 15: 713, 2015 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-26474549
6.
The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials.
Ann Oncol
; 25(1): 276-82, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24356639
7.
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors.
Invest New Drugs
; 32(3): 436-44, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24258465
8.
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.
Invest New Drugs
; 32(6): 1204-12, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24919855
9.
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Ann Oncol
; 24(12): 3004-11, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24158411
10.
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Ann Oncol
; 24(9): 2256-61, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23676418
11.
Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.
Ann Oncol
; 24(3): 838-42, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23139256
12.
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.
Ann Oncol
; 24(8): 2158-65, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23576709
13.
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience.
Ann Oncol
; 23(8): 1963-1967, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22377564
14.
Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.
Ann Oncol
; 23(11): 2960-2963, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22745218
15.
A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Cancer Chemother Pharmacol
; 76(3): 597-603, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26210681
16.
Body composition and survival in the early clinical trials setting.
Eur J Cancer
; 49(15): 3068-75, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23867127
17.
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
Cancer Chemother Pharmacol
; 69(5): 1117-26, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22205203
Resultados
1 -
17
de 17
1
Próxima >
>>